Avalo Therapeutics, Inc. (AVTX) Stock Price & Analysis

Avalo Therapeutics, Inc. (AVTX) rose 1.25% to USD 19.47 as of September 8, 2026 at 14:05 UTC, according to Nexqual real-time market data.

AVTX last closed at USD 19.47; the session ranged USD 18.95–19.5 on volume of 45,548 shares. Market capitalization is —, with a 52-week range of USD 9.54–24.27 (NCM). Source: Nexqual, September 8, 2026 at 14:05 UTC.

Key Statistics (as of September 8, 2026 at 14:05 UTC)

Technical Analysis (AVTX)

Nexqual's technical model rates AVTX "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of September 8, 2026 at 14:05 UTC.

From Avalo Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)

Key Strengths & Strategy (as disclosed to the SEC)

• United States Government Regulation In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act ("FDCA"), the Public Health Service Act, and its implementing regulations.
• State and foreign laws, including for example the European Union General Data Protection Regulation, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
• Intellectual Property Overview Our success depends in part on our ability to obtain and maintain proprietary protection for the technology and know-how upon which our product candidates are based, to operate without infringing the proprietary rights of third parties and to prevent third parties from infringing our proprietary rights.
• We also rely on trade secrets and proprietary know-how, including manufacturing and formulation know-how, as well as confidentiality agreements and other contractual protections, to protect aspects of our technology and product candidates that may not be patentable or that we elect not to patent.

Partnerships

• We are responsible for the development and commercialization of the program. 2 Table of Contents We are required to pay Lilly up to $70 million based on the achievement of specified development and regulatory milestones.
• Upon commercialization, we are required to pay sales-based milestones aggregating up to $650 million payable to Lilly and up to $70 million to Leap.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 14:05 UTC. This page is informational and not investment advice.